EDX Medical Group has signed a distribution agreement with Caris Life Sciences® (Caris), a leading US-based next-generation AI TechBio and precision medicine company. Under the agreement, EDX Medical and Caris will work together on a mutually exclusive basis in the United Kingdom (UK) and Nordic countries for a minimum of three years to distribute Caris’ portfolio of advanced and comprehensive molecular profiling services for clinical and research use. Professor Sir Chris Evans, OBE, founder of EDX Medical, said: “The signing of this agreement signifies a further major step forward in our strategy to provide clients with access to world-class diagnostic tools and services that can change the detection, treatment and outcome of cancer for patients. “The pace of scientific advancement is such that for a patient with cancer who may only be able to provide one sample and urgently needs to start optimal treatment, reviewing their whole exome and transcriptome rather than a smaller selection of genes limited by current knowledge is clearly the most robust clinical approach. We could not wish for a better partner in this field than Caris.” Read more:- https://lnkd.in/e_URApEP #EDXMedical hashtag #HealthcareInnovation hashtag #PointOfCareTesting hashtag #MedicalAdvancements hashtag #diagnostics hashtag #cancerdiagnostics hashtag #cancer
EDX Medical Group’s Post
More Relevant Posts
-
What technology do you think has the most potential to transform medicine? Inspired by RNA therapies for personalized cancer treatment or genetic disease, combined with the power of AI/ML in developing the therapies for optimizing both the nucleic acid cargo and delivery vehicle.
Executive Vice President at Thermo Fisher Scientific. Leads technology businesses. Passionate about excellence and digital innovation in life science and diagnostics. Precision Medicine
For years we have seen the power of technology to transform medicine. From the introduction of X-ray to the emergence of spatial biology allowing scientists to observe cells in 3D. Healthcare's technological transformation motivates me every day, particularly since we are accelerating bringing technology and science together to empower people around the world to make data-driven decisions about their health. Most recently, a study published in Nature Portfolio demonstrates the potential of what scientists call a "functional #precisionmedicine approach" to slow cancer progression through highly personalized, actionable treatment plans. Is a small study but a material impact, showing how "Out of six patients who received these guided therapies, five showed strong improvements in their progression-free survival—this time outpacing the periods they had spent cancer-free, before the disease returned after at least two initial treatments." Building on years of progress in precision oncology, the study offers hope to patients and families that we can more effectively target and treat cancer. Which technology do you think has the most potential to transform medicine?
Precision medicine approach combining AI, DNA and drug testing shows gains against relapsed childhood cancers
fiercebiotech.com
-
Executive Vice President at Thermo Fisher Scientific. Leads technology businesses. Passionate about excellence and digital innovation in life science and diagnostics. Precision Medicine
For years we have seen the power of technology to transform medicine. From the introduction of X-ray to the emergence of spatial biology allowing scientists to observe cells in 3D. Healthcare's technological transformation motivates me every day, particularly since we are accelerating bringing technology and science together to empower people around the world to make data-driven decisions about their health. Most recently, a study published in Nature Portfolio demonstrates the potential of what scientists call a "functional #precisionmedicine approach" to slow cancer progression through highly personalized, actionable treatment plans. Is a small study but a material impact, showing how "Out of six patients who received these guided therapies, five showed strong improvements in their progression-free survival—this time outpacing the periods they had spent cancer-free, before the disease returned after at least two initial treatments." Building on years of progress in precision oncology, the study offers hope to patients and families that we can more effectively target and treat cancer. Which technology do you think has the most potential to transform medicine?
Precision medicine approach combining AI, DNA and drug testing shows gains against relapsed childhood cancers
fiercebiotech.com
-
Today we are incredibly thrilled to finally announce our partnership with Bruker Bruker JPK BioAFM, a business unit of Bruker (NASDAQ: $BRKR) to accelerate the development of a completely new IVD diagnostic modality, leveraging the power of mechanobiology + AI. Cancerous cells feel different to the touch. Uncovering the richness in cellular biophysical properties data helps physicians recognize exactly when the tumor has recurred or not. At Cellens, we are using AI to unlock multi-parametric biophysical markers that can detect cancer non-invasively and accurately while saving costs every step of the way for our healthcare systems and providers. Ultimately, providing greater and faster access to quality care to many more cancer patients. This announcement is well timed as we recently generated a new set of clinical feasibility data with outstanding performance via multi-center, prospective clinical studies. Stay tuned to learn more about results in the coming months! For more information: [email protected] #noninvasive #cancerdetection #mechanobiology #AI #BrukerBioAFM #Cellens
Cellens Announces Collaboration with Bruker BioAFM to Advance Mechanobiology Technology for Cancer Detection
businesswire.com
-
With the rise of high throughput technologies, including artificial intelligence, big data analytics, and next-generation sequencing, along with the availability of patient databases, precision #oncology has achieved success in improving patient outcomes. https://hubs.la/Q02w-r0q0
Global Oncology Precision Medicine Market to Reach $364 Billion by 2035
blog.marketresearch.com
-
Working on building better human disease models. Adding value to life science companies.
Tons of great MEA and iPSC #data in this new white paper from Axol Bioscience Ltd. and Axion BioSystems! See how we characterized a set of iPSC derived motor neurons using MEA to support ALS drug discovery and research #ipscs
iPSC—MEA data alert! Axol has published a new whitepaper showing characterization data of a human iPSC-derived motor neuron disease model for ALS drug discovery using Axion BioSystems' Maestro Pro. We have recently published a new whitepaper where we collaborated with Axion BioSystems by using their Maestro Pro to characterize a human iPSC-derived motor neuron disease model for ALS drug discovery. Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease, characterized by the progressive loss of motor neuron function, of which there is currently no cure. With current treatment aimed mainly at symptomatic relief, there is a need for better treatment options for patients with this debilitating disease. Key to this, is having better in vitro models of ALS that are more translational relevant. At Axol, our work in the iPSC space aims to support the industry's journey towards this through the production of iPSC-derived motor neurons fit for disease modelling. We understand the importance of characterizing these cells to ensure that are functionally relevant. This is essential for establishing reliable disease models, as it ensures that the cells accurately reflect the key pathological features of ALS, such as hyperexcitability. In this whitepaper, we characterized motor neurons morphologically and functionally, via multielectrode array from 4 different lines. The data illustrated in the whitepaper demonstrated how the ALS phenotype lines displayed a reproducible loss of synchronous firing and different degrees of hyperexcitability. This is in accordance with expected ALS clinical pathology and supports the case for the use of these cells in experimental in vitro models to study ALS pathology and potential therapeutics. Read the full whitepaper here: https://hubs.la/Q02VQ2Px0 Learn more about axoCells Motor Neurons: https://hubs.la/Q02VQ0vF0 If you have any questions, contact us at [email protected]. #iPSCs #MotorNeurons #MEA #ALS
-
-
A new study published in Nature Medicine has provided an unprecedented look into the tumor microenvironment of metastatic breast cancer. By combining single-cell RNA sequencing with four spatial expression assays, researchers created a detailed map of 67 tumor biopsies from 60 patients. This map reveals the cellular diversity within these tumors and how different cell types interact with each other across nine anatomical sites. This research has significant implications for understanding how metastatic breast cancer develops and spreads, potentially leading to new diagnostic tools and treatment strategies. #metastaticbreastcancer #cancerresearch #precisionmedicine #tumormicroenvironment
Understanding the Tumour Microenvironment is critical to developing new cancer treatments. In this paper by Klughammer and almost 60 other authors, use 8 spatial and single cell/nucleus methods to map the TME in unprecedented detail. The first thing that stands out to me is that patient-to-patient variability accounts for the majority of the variance seen. Meaning that personalised medicine really is the future - we have to target the right drugs to the right people. Interestingly the immune compartment variability is NOT explained by patient-to-patient differences. The second stand out part for me is that large datasets from multiple assays requires a HUGE amount of QC. All current and future clinical trials and drug development platforms will need to standardise data both internally and externally to feed the AI machines. These models will then help guide the next generation of drug products faster and more accurately. GIGO The final stand out for me was that even with this huge amount of data they were still not able to perform robust statistical analysis at a clinically relevant level because the numbers (60 patients/67 samples) were too small. Long gone are the days where an n of 4 was good enough, even when the hypothesis being tested is very tightly defined. https://lnkd.in/eXbbryYV #CancerResearch #PersonalisedMedicine #TumourMicroenvironment #ImmunoOncology #SingleCellAnalysis #ArtificialIntelligence #BigData #TranslationalScience #PrecisionMedicine
A multi-modal single-cell and spatial expression map of metastatic breast cancer biopsies across clinicopathological features - Nature Medicine
nature.com
-
Brain tumors, both primary and metastatic, are devastating diseases with a five-year overall survival rate of less than 35%. Despite over 1,000 clinical trials to date, effective treatments remain elusive. The grand challenge is that current drug development and clinical trials are not based on preclinical models that accurately capture disease heterogeneity and most importantly, predict patient responses. AIPTO TechBio addresses this challenge with its revolutionary platform, featuring clinically validated, next-generation patient avatar technology. This technology precisely replicates the cellular and molecular pathology of patients' tumors, including the complex tumor microenvironment. By harnessing the power of generative AI, AIPTO fully exploits patient drug response data, enabling the creation of state-of-the-art AI models. The AIPTO platform represents a paradigm shift in cancer research and drug development, transforming key processes such as target discovery, lead validation, biomarker identification, and patient population stratification. Ultimately, AIPTO is poised to revolutionize drug discovery and deliver groundbreaking therapies for brain cancer patients. Meet AIPTO TechBio GmbH @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW
-
-
Clinical Trials Facilitation and Management Medical Quality Assurance Consulting & Pioneering Medical Strategist in Oncology/ Haematology Clinical Trials
Relevant findings from a recent study on AI-enabled multi-trial matching systems by Massive Bio In a conversation with CancerNetwork® during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Arturo LoAIza-Bonilla MD MSEd, FACP, the health system director of Research and medical director of Oncology Research at Capital Health in Pennington, New Jersey, spoke about his research in developing an AI-enabled system intended to reduce the time and resources needed to match patients to trials. ▶️Effect of a novel artificial intelligence (AI) –enabled multi-trial matching system on patient matching using real-world data. This study demonstrated a significant increase in potential matches and a reduction in matching time, with patients being matched to 1.82 times more trials using AI compared to human matching. Implementing NGS testing could double the number of trial matches, ensuring patients receive the right biomarker testing. 🚩The most impressive result? The AI system accomplished in 1 hour what would have taken 19,500 hours manually. This drastic reduction in manual effort allows us to focus more on patient care, delivering excellent support. Reference: Kurnaz S, Loaiza-Bonilla A, Castañeda DC, Huner O. J Clin Oncol. 2024;42(suppl 16):e13501. doi:10.1200/JCO.2024.42.16_suppl.e13501. Our dedicated leadership team: Selin Kurnaz, PhD | Arturo LoAIza-Bonilla MD | Çağatay M. Çulcuoğlu #AI #ClinicalTrials #HealthcareEfficiency #ClinicalTrialMatching #PrecisionOncology #RightPatient #RightTime #ImprovEfficiency #AIinClinicalpractice
Artificial Intelligence Tool May Improve Oncology Multi-Trial Matching
cancernetwork.com
-
🔦 Here’s this week’s round-up of exciting news from across our portfolio: 🎥 Oxford Ionics on CNBC Chris Ballance, Co-Founder & CEO of Oxford Ionics, spoke to CNBC about the transformative potential of quantum computing. 🌟CEO of OMass Therapeutics wins major award Congratulations to Ros Deegan, CEO of OMass Therapeutics for winning this year’s Women-Led Business Leader of the Year, at the Life Star Awards! A well-deserved recognition for Ros’ incredible leadership. 💉 Theolytics Begins First-In-Human Trial Theolytics has dosed the first patient in their Phase I/IIa trial of THEO-260, a novel oncolytic immunotherapy for advanced-stage platinum-resistant ovarian cancer. This milestone marks a major step forward in tackling the challenging disease. 🏆 Neu Health bestowed NHS Journal Award Congratulations to the Neu Health team for winning the NHS Journal Award for digitising patient care. Awarded at an event with over 2,000 people, opened by the Secretary for State for Health, Wes Streeting, the awards honour exceptional achievements in the NHS. 🏢 Oxford University Innovation in Forbes “Each company formed represents major progress,” says Dr Mairi Gibbs, CEO of OUI, featured in a recent Forbes piece speaking about how spinout creation has continued to accelerate despite current state of capital markets. 🩺 FDA Recognition for Ultromics Ultromics achieved FDA Breakthrough Device Clearance for its cardiac amyloidosis screening device, enhancing early detection capabilities for a condition often diagnosed too late.
-
-
SVP Marketing & Corporate Strategy at Axion BioSystems | PhD | Discover the Functionality of Your Cells
📢 NEW: #ALS Drug Discovery - MEA characterization of human iPSC-derived motor neuron disease model. 5 Key Findings: 🟠 Four human iPSC lines, 3 from donors with ALS and 1 unaffected donor, were successfully differentiated to functional motor neurons. 🟠 The use of the ‘Accelerator’ supplement to mimic in vivo like environment enabled assay ready, functional firing of motor neurons in ~10 days. 🟠 Used in conjunction with the Maestro Pro MEA system, the ”thaw-to-data” time was ~20 days. 🟠 Motor neurons derived from ALS donor iPSCs were morphologically different to those from unaffected donors. 🟠 Through MEA analysis, morphological differences corresponded to functional phenotype differences including the key attribute of hyperexcitability. A great collaboration with the team at Axol Bioscience Ltd. Learn more in the post below. #STEMCELLS, #Neuroscience, #AxionBio
iPSC—MEA data alert! Axol has published a new whitepaper showing characterization data of a human iPSC-derived motor neuron disease model for ALS drug discovery using Axion BioSystems' Maestro Pro. We have recently published a new whitepaper where we collaborated with Axion BioSystems by using their Maestro Pro to characterize a human iPSC-derived motor neuron disease model for ALS drug discovery. Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease, characterized by the progressive loss of motor neuron function, of which there is currently no cure. With current treatment aimed mainly at symptomatic relief, there is a need for better treatment options for patients with this debilitating disease. Key to this, is having better in vitro models of ALS that are more translational relevant. At Axol, our work in the iPSC space aims to support the industry's journey towards this through the production of iPSC-derived motor neurons fit for disease modelling. We understand the importance of characterizing these cells to ensure that are functionally relevant. This is essential for establishing reliable disease models, as it ensures that the cells accurately reflect the key pathological features of ALS, such as hyperexcitability. In this whitepaper, we characterized motor neurons morphologically and functionally, via multielectrode array from 4 different lines. The data illustrated in the whitepaper demonstrated how the ALS phenotype lines displayed a reproducible loss of synchronous firing and different degrees of hyperexcitability. This is in accordance with expected ALS clinical pathology and supports the case for the use of these cells in experimental in vitro models to study ALS pathology and potential therapeutics. Read the full whitepaper here: https://hubs.la/Q02VQ2Px0 Learn more about axoCells Motor Neurons: https://hubs.la/Q02VQ0vF0 If you have any questions, contact us at [email protected]. #iPSCs #MotorNeurons #MEA #ALS
-
